Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

VCA-894A

Oligonucleotide (Antisense oligonucleotide) · Gene silencing · developed by Vanda Pharmaceuticals

Phase 1/2 Most advanced trial

VNDA Developer

1 Registered trials

What is VCA-894A?

VCA-894A is an intrathecal antisense oligonucleotide injection being studied in Charcot-Marie-Tooth disease and neuromuscular diseases.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Oligonucleotide (Antisense oligonucleotide)
Mechanism: Gene silencing
Therapy area: Neurology
Developer: Vanda Pharmaceuticals (VNDA)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07223632	Phase 1/2	Charcot Marie Tooth Disease (CMT)	Active not recruiting	VNDA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Charcot Marie Tooth Disease (CMT)Neuromuscular Diseases (NMD)

More from Vanda Pharmaceuticals

Iloperidone FDA approved Milsaperidone FDA approved Ponesimod FDA approved Tasimelteon FDA approved Tradipitant FDA approved Trichostatin A Phase 2 VQW-765 Phase 3 VSJ-110 Phase 2

Sources

ClinicalTrials.gov NCT07223632

Updated Oct 3, 2026. Something wrong or missing? Report it on the VNDA page.

Follow VNDA, the company behind VCA-894A

See VNDA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VNDA catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z